BioCardia, Inc. (NASDAQ:BCDA) Expected to Post Earnings of -$0.31 Per Share

Wall Street analysts expect that BioCardia, Inc. (NASDAQ:BCDA) will announce earnings of ($0.31) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for BioCardia’s earnings. BioCardia reported earnings of ($0.51) per share during the same quarter last year, which indicates a positive year over year growth rate of 39.2%. The business is scheduled to announce its next earnings results on Thursday, April 8th.

On average, analysts expect that BioCardia will report full-year earnings of ($1.67) per share for the current financial year, with EPS estimates ranging from ($1.75) to ($1.59). For the next financial year, analysts forecast that the company will report earnings of ($0.82) per share, with EPS estimates ranging from ($1.10) to ($0.53). Zacks’ EPS averages are an average based on a survey of analysts that cover BioCardia.

A hedge fund recently bought a new stake in BioCardia stock. Bank of New York Mellon Corp acquired a new position in shares of BioCardia, Inc. (NASDAQ:BCDA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,294 shares of the company’s stock, valued at approximately $56,000. Bank of New York Mellon Corp owned about 0.13% of BioCardia as of its most recent SEC filing. 9.01% of the stock is owned by hedge funds and other institutional investors.

Shares of BCDA traded up $0.08 during trading hours on Tuesday, hitting $4.26. The company had a trading volume of 456,339 shares, compared to its average volume of 438,227. The business has a fifty day moving average of $4.30 and a 200-day moving average of $3.39. The company has a quick ratio of 1.99, a current ratio of 1.99 and a debt-to-equity ratio of 0.05. The firm has a market cap of $52.95 million, a price-to-earnings ratio of -2.20 and a beta of 1.98. BioCardia has a 12 month low of $1.91 and a 12 month high of $8.60.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

Featured Article: Equal Weight Rating

Get a free copy of the Zacks research report on BioCardia (BCDA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with's FREE daily email newsletter.